SUBJECT INDEX

Notes: Gene names are listed separately in the Gene Index. Specific chromosomal locations (e.g., 1q21.1, 22q11.2, etc.) are listed under “Chromosomal locations”. Where terms occur in a heading or subheading, the page numbers are listed in bold. Figure page numbers are italicized and Table page numbers are underlined. Frequently occurring terms such as autism, epilepsy, intellectual disability, schizophrenia, deletion, duplication, etc., are not indexed, as they occur throughout the text.

Abuse, 33
ADHD. see Attention-Deficit Hyperactivity Disorder
Age, paternal, 36, 59, 61, 84, 90, 113, 115–16, 210
Agenesis of the corpus callosum, 14, 166, 174, 218
Aggregate score, 76
AKT, 141–2, 203, 210, 322, 324–5, 331
Albinism, 163, 164
Allelic heterogeneity. see Heterogeneity, allelic
Alpha2-chimaerin, 162
Alzheimer’s disease, 240–52
Amish lethal microcephaly, 134
AMPA receptor, 214–16, 324
Amygdala, 168, 218, 276
Aneuploidy, 300
Angelman syndrome, 9, 11, 37, 197, 204, 243, 250, 270, 276–7, 324, 335
Anxiety, 70, 145, 171–2, 214, 276, 327
Apert syndrome, 116
ARC complex, 208, 211
Asperger, H., 31
Asymmetry, fluctuating, 83–4, 86, 88, 89
Ataxia, 13, 29, 35, 250, 270
Ataxia, cerebellar, 13, 35
Attention, 100, 249, 270, 276, 282, 284, 319
Attention-Deficit Hyperactivity Disorder, 8, 10, 13, 30–39, 86, 99–100, 145, 170, 207–12, 216, 220, 296
Autophagy, 211
Axon guidance, 40, 137, 142, 144, 155–76, 214, 218, 239, 326
BAF complex, 219
Baraitser-Winter syndrome, 56, 137
Bardet-Biedl syndrome, 76, 292
Basal ganglia, 135, 171–2
Bateson, W., 69, 71, 290, 303
Bilateral frontal polymicrogyria. see Polymicrogyria
Bipolar disorder, 8, 10, 30–40, 93, 145, 198–200, 207, 218, 294, 334
Bleuler, E., 30, 294
Bohring-Opitz syndrome, 55
Brachydactyly mental retardation syndrome, 205, 219

© 2015 John Wiley & Sons, Inc. Published 2015 by John Wiley & Sons, Inc.
Subject Index

Broad autism phenotype, 16, 214
Buffering, 13, 72, 85, 101–102
C. elegans, 70, 158, 264, 270
Canalization, 72, 82, 101, 103, 299
Cancer, 113, 121, 141, 143, 217, 219, 262, 292, 294, 300
Cannabis, 98, 118–19
Cav1.2, 248–9
CD/CV model, 3, 4, 50, 60
CDPPB, 323, 324, 330
CD/RV model, 50
Cell adhesion, 40, 49, 196, 208–13, 220
Cell cycle, 130, 132, 137, 325
Cell death, 130–33, 173
Cell fate, 132–3, 253
Cell migration. see Migration, cell/neuronal
Centrosome, 131, 132–5
Cerebellum, 139, 144, 168, 212, 277, 281
Cerebral organoids, 251
Cerebral palsy, 29
CFEOM. see Congenital fibrosis of the extraocular muscles
CGH. see Comparative Genome Hybridization
Charcot-Marie-Tooth neuropathy, 297
Chromatin, 17, 133, 197, 204, 209, 218–20
Chromosomal locations
1p36.11, 204
2p16.3, 37, 199
6p21.32, 203
6p25, 12
9p24.3, 205
12p13.1, 202
12p13.33, 201
16p11.2, 12, 36, 38, 145, 206, 207, 263
16p13.1, 36, 38, 5T, 207
16p13.2, 201
16p13.3, 204
17p12, 50
19p13.2, 206
1q21.1, 12, 36, 37, 51, 207
1q42.2, 200
2q24, 218
2q24.2, 206
2q24.3, 202
2q37.3, 205, 219
3q29, 12, 37, 215
5q14.3, 205, 219
6q25.3, 204
7q11.23, 37, 50, 207, 275
7q36.3, 37, 208
9q34.3, 205, 208
9q34.11, 203
9q34.13, 204
10q23, 12, 203
10q23.31, 203
10q24, 199
11q13.3, 200
11q24.2, 61
13q31.1, 170, 199
15q11.2, 12, 36, 37, 204
15q13.3, 12, 36, 38, 201, 207
17q11.2, 203
17q12, 12, 36, 38, 207
17q21.2, 206
17q21.3, 50
18q21.2, 35, 61
22q11.2, 12, 19, 36, 38, 58, 74, 100, 141, 207, 293–4, 296
22q11.23, 206
22q13.2, 204
22q13.33, 200, 208, 216
7p35-q36.1, 198
Xp11.4, 200
Xp11.2, 202
Xp11.23, 203
Xp22.3, 53, 199
Xp22.13, 202
Xp21.2-p21.3, 198
Xp22.32-p22.31, 199
Xq13.1, 199–200
Xq22.1, 199
Xq24, 202
Xq25, 201
Xq27.3, 202
Xq28, 198, 203
Xq13-q21, 53, 199
Chromosomal Microarray (CMA), 300–301. see also Comparative Genome Hybridization
Cilia, 143–4, 164
Ciliopathy. see Cilia
Clinical genetics, 36, 220
Clouston, Thomas, 30
CMA. see Chromosomal Microarray (CMA)
CNP. see Polymorphism, copy number
CNTNs in Gene Index, 212, 214
Cobblestone lissencephaly. see Lissencephaly, cobblestone
Cockayne syndrome, 132
Coffin-Siris syndrome, 56, 204, 206–207, 219
Cognition, 144, 146, 270–71, 276, 278, 284, 333
Cohen syndrome, 133, 144
Commissure, 157, 165–6, 184
Common Disease/Common Variants model. see CD/CV model
Common Disease/Rare Variants model. see CD/RV model
Communication, 263, 277, 279, 282–3
Comorbidity, 31–2, 82, 85–8, 170–71
Comparative genome hybridization, 12, 50. see also Chromosomal microarray
Congenital cranial dysinnervation disorder, 160–61
Congenital fibrosis of the extraocular muscles, 136, 160–63
Congenital innervation disorder, 160–61
Connectivity, brain/neuronal, 14, 155, 173, 196–7, 214, 240, 247, 249, 264, 321–2, 335
Consanguinity, 39, 53–4, 89, 95. see also Inbreeding
Contactin, 196, 212, 214, 218. see also CNTNs in Gene Index
Copy number variant. see CNV
Corpus callosum, 14, 136, 156, 165–6, 171, 174, 176, 198, 203–204, 214, 218
Cortical dysplasia. see Dysplasia, cortical
Cortical malformation. see Malformation, cortical
CRASH syndrome, 156, 164
CRISPR/Cas, 268
Cryptic genetic variation, 13, 15, 72, 101, 103
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide. see CDPPB
Cystic fibrosis, 13, 291, 299–300
De novo mutation. see Mutation, de novo
Deep brain stimulation, 333
Deletion. see CNV
Delusions, 30, 166, 249
Dementia praecox, 30
Dendritic spines, 211–16, 248, 321–2, 335
Depression, 8, 17, 32, 36, 157, 172, 200
Developmental delay, 11, 33, 36–9, 132, 213, 219–20, 250, 276, 300
Developmental instability (DI), 81–9, 101–103
Developmental variation, 14–15, 81, 86, 87, 91, 220
Dextromethorphan, 321, 323
Diabetes, 29, 33, 39, 72, 75, 115, 301
Diagnostic and Statistical Manual of Mental Disorders 5 (DSM5), 31
Diffusion tensor imaging, 166–7
DiGeorge syndrome. see Velocardiofacial syndrome
Dopamine or dopaminergic, 119, 167, 196, 212, 217, 245, 246, 322, 333
Double cortex, 130, 135, 136, 141
Dravet syndrome, 13, 202, 213, 216, 269
Drosophila, 70, 84, 114, T61, 168, 264, 270
DTI. see Diffusion tensor imaging
Duane syndrome, 156, 160, 162
Duplication. see CNV
Dwarfism, 6, 131, 293
Dyslexia, 1, 13, 29–30, 145, 277
Dysmorphology, 36, 37, 55, 131, 133, 137, 141, 198, 207, 214, 219
Dysplasia, cortical, 141, 143, 198, 212
Dyspraxia, 29
Dystroglycan, 137–41, 145, 159
Dystrophin, 11, 137
ECM. see Matrix, extracellular
Embryonic stem cell. see Stem cell, embryonic
Emergent phenotypes, 17, 275
Emotional regulation, 29
Encephalopathy, epileptic, 35, 199–205, 216–19
ENCODE Project, 40, 91
Endophenotype, 3, 6–8, 55, 94, 97–9
Enhancer, 70
Environment, family or shared, 15, 95, 119
Environment, non-shared, 15, 119
Eph-R, 159, 164–7, 175
Ephrin, 159, 164–7, 175
Epigenetic (modifications), 91, 112, 116, 130, 146, 250, 263, 281, 289, 332
Epigenetic landscape, 15, 83
Epileptic encephalopathy. see Encephalopathy, epileptic
Epistasis, 13, 16, 69–74, 98, 296–8, 304
Epistatic interaction. see Epistasis
ES cell. see Stem cell, embryonic
Executive function, 3, 17, 97, 98
Exome sequencing. see Sequencing, exome
Expressivity, 11, 19, 74, 208, 263, 291
Familial amyloid polyneuropathy, 74
Familiality, 5
Family environment. see Environment, family or shared
Fetal alcohol syndrome, 29
FISH, 50
Fisher, R., 71
Fitness, 4, 10, 55–6, 60–61, 75, 82–8, 92, 95
Fluctuating asymmetry. see Asymmetry, fluctuating
Fluorescent in situ hybridization. see FISH
FMR1 in Gene Index, 202, 240, 250, 263, 276, 326, 328
FMRP. see Fragile X, protein
Focal cortical dysplasia, 141, 143
Folate, 29, 34, 112, 114, 115, 120
Folic acid. see Folate
Fragile X gene (see FMR1 in Gene Index)
protein, 58, 210–19, 250, 263, 324, 328
GABA, 196, 271, 333
receptor, 216, 269, 271, 321, 322, 323, 329
GABAergic (system), 168, 244–5, 321, 322, 323, 329
GCTA, 8, 18
Gene by environment interaction, 14, 304
Gene-by-environment interaction, 14, 117–20, 304
Genetic background. see Background, genetic
Genetic variance. see Variance, genetic
Genome-wide association study. see GWAS
Genome-wide complex trait analysis. see GCTA
Germline, 52, 57, 59, 143, 249, 295, 300, 329
Gibson, G., 72
Gigantism, 7, 293
Glia, 129, 142, 244, 265, 329
Glia, midline, 166
Glia, radial, 138, 244, 255
Globus pallidus, 171
Glutamatergic (system), 167–8, 208–209, 212, 216–19, 244, 321, 325
Glycine, 216, 321
Glycosylation, 139, 169
GnRH neurons, 326
GSK3, 52, 57, 59, 143, 249, 295, 300, 329
Gibson, G., 72
Gigantism, 7, 293
Glia, 129, 142, 244, 265, 329
Glia, midline, 166
Glia, radial, 138, 244, 255
Globus pallidus, 171
Glutamatergic (system), 167–8, 208–209, 212, 216–19, 244, 321, 325
Glycine, 216, 321
Glycosylation, 139, 169
GnRH neurons, 176
GSK3, 166, 174–5, 322, 323, 325, 330
GTPase, 56, 162, 203, 208–209, 214, 217–18, 324, 329
Gurdon, J., 242–3
GWAS, 7–9, 13, 18, 34–5, 39–40, 60–61, 72–6, 94, 102, 120–21, 167, 212, 293
GxE interaction. see Gene by environment interaction
Handedness, 86
Haploinsufficiency, 35, 204–205, 209, 218–20, 269, 331
Haplotype, 7–9, 167–8, 297
Haplotype map. see HapMap Project
HapMap Project, 7, 34, 60
Height, 6, 39, 72, 84, 293
Hemimegalencephaly, 141, 142
Heparan sulfate proteoglycan, 159
Heritability, 3, 6, 8, 11, 15, 18–19, 32, 35–6, 39, 58, 61, 71, 84–5, 95–6, 118–19, 249, 294
Heterogeneity, allelic, 11, 15
Heterogeneity, clinical or phenotypic, 55, 74, 139, 143, 294
Heterogeneity, genetic/focus, 2–6, 13, 15–18, 56, 72, 74, 94, 294, 304
Heterotopia, periventricular nodular, 15, 130, 135–7, 141, 174
Hetrotopia, periventricular nodular, 130, 136, 137
HGPPS, 156, 162, 165
High-risk mutation. see Mutation, high-risk
Hippocampus, 144, 157, 162, 197, 212, 245, 247, 271, 321, 329
Hirschsprung disease, 6, 13, 16, 20, 55, 74, 76
Homeostasis, circuit or synaptic, 75, 197
Horizontal gaze palsy with progressive scoliosis. see HGPPS
hPSC. see Stem cell, human pluripotent
HSPG. see Heparan sulfate proteoglycan
Huntington’s disease, 13, 112, 243, 291
Hyperactivity, 17, 31, 250, 319, 330. see also ADHD
IGF1, 221, 270, 323, 325, 328, 331
Immune activation, maternal, 33, 114
Inborn errors of metabolism, 11. see also Metabolic disorder/deficiency
Inbreeding, 53, 84, 89–91, 100, 102. see also Consanguinity
Infection, 14, 29, 33, 85, 111–15, 117, 120–21, 145, 169
Inheritance, autosomal dominant, 55–6, 162–5, 199, 214–15, 248
Inheritance, digenic, 16, 75
Inheritance, Mendelian, 2, 5, 7, 13, 29, 34–5, 39, 54, 69, 291, 295
Inheritance, oligogenic, 11, 16, 74–5, 291–2, 296
Inheritance, polygenic, 2–7, 16, 59, 61, 94–5, 101, 120, 211, 293, 296, 298, 331
Inheritance, recessive, 2, 35, 39, 50, 53–5, 95, 130, 133–9, 144–5, 161, 165, 198–9, 212–13, 216, 251, 269, 282, 292
Intelligence, 53, 88–91, 95–9. see also IQ
Interneuron, 164–5, 171, 197, 212, 245–8
iPS cells. see Stem cell, induced pluripotent
IQ, 7, 54, 95–6, 99–100, 119. see also Intelligence
Jackson, Hughlings, 30
Joubert syndrome, 143, 156, 164
JSRD. see Joubert syndrome
Kabuki syndrome, 55
Kainate receptor, 197
Kanner, L., 31
KBG syndrome, 55
Kleefstra syndrome, 197, 205, 208
Klippel-Feil syndrome, 164
Knobloch syndrome, 139
Kraepelin, E., 30–32
Language, 276–9, 283–4
Language impairment, 115, 204–206, 208, 319
Language impairment, specific, 1, 277, 284. see also Language Impairment
Learning and memory, 114, 168, 197, 219, 251, 264, 324, 330
Learning disability or disorder, 31, 203, 250
Lesch-Nyhan syndrome, 52, 240, 243
Liability, 3, 8, 18–19, 36, 39, 98
Liability-threshold model, 3
Lig 4 syndrome, 132
Linkage, 2, 5–6, 12, 39, 53–4, 56
Lissencephaly, 130, 131, 134–41
Lissencephaly, cobblestone, 138–40
Lissencephaly with cerebellar hypoplasia, 138
Locus heterogeneity. see Heterogeneity, genetic/locus
Long-term depression. see LTD
Long-term potentiation. see LTP
LTD, 197, 217, 219, 267, 324
LTP, 168, 197, 217, 267, 270–71, 324, 329
Machine learning, 72–4
Magnetic resonance imaging, 8, 143, 162–3, 166–7, 335
Magnetic resonance spectroscopy, 90
Malformation, cortical, 11, 129, 135–45
MASA syndrome, 166
Maternal immune activation. see Immune activation, maternal
Matrix, extracellular, 135–40, 158
Meckel-Gruber syndrome, 143
Megalencephaly, 130, 141–2
Memory. see Learning and memory
Memory impairment, 166, 173
Mendelian. see Inheritance, Mendelian
Mental retardation. see Retardation, mental
Metabolic disorder/deficiency, 17, 29, 134, 240, 282, 326
Metabotropic glutamate receptor, 99, 197, 209, 216–7, 265, 267, 321, 328
mGluR5, 323, 324, 328–30
MIA. see Maternal immune activation
Microcephaly, 35, 38, 55, 130–34, 135, 137, 141, 144–5, 200, 205, 251
Microglia, 173
Microlissencephaly, 131, 134
Migrant, 33–4, 113, 116–17, 119
Migration, cell/neuronal, 135–8, 158–9, 162–3, 166–8, 176, 210–14, 218–19, 253, 326
Miller syndrome, 297
Minor physical anomalies, 82–3, 85–6, 95, 294
Mitochondria, 134, 263, 276
Modifier, genetic, 4–5, 9, 11, 16, 18, 75, 262–3, 269, 303
Mosaicism, germline, 57, 295
Mosaicism, somatic, 141–2, 289–91, 295, 303
Motor function, 29, 241
Motor neuron, 160–61, 164, 175, 246
Mowat-Wilson syndrome, 55
MPAs. see Minor physical anomalies
MRI. see Magnetic resonance imaging
MRS. see Magnetic resonance spectroscopy
mTOR, 141–3, 203–204, 210, 222, 324, 324–5, 329–31
Multielectrode array, 333
Multifactor dimensionality reduction, 73
Multiple sclerosis, 243
Muscular dystrophy, 11, 137–9, 145
Mutation, de novo, 2–5, 10, 36, 50–59, 81, 90, 95–6, 116, 135, 207–216, 249, 294–7
Mutation, high-risk, 2, 7, 11, 12, 17–18, 20, 73, 75
Mutation load, 81–102
Mutation, rare, 4, 6, 9–10, 13–14, 34, 36, 51, 53, 75–6, 167, 198–206, 208–214, 218, 296, 301. see also Variant, rare
Mutation rate, 36, 39, 51, 55, 58, 59, 90, 268
Mutation, somatic, 116, 141–3, 145–6
Mutational target, 4, 56, 196
Mutation-selection balance, 59, 102
Myelin or myelination, 159, 276, 329
NAHR. see Non-allelic homologous recombination
Neocortex. see Cortex, cerebral
Neural stem cell. see Stem cell, neural
Neurexin, 36, 39, 98, 208, 212, 322. see also NRXN1 in Gene Index
Neuroconstructivism, 275–9, 284–5
Neurofibromatosis, 203, 209, 217, 270, 321–5, 328, 329
Neurofibromin, 203, 217, 323, 329. see also NF1 in Gene Index
Neurogenesis, 131, 133, 136, 208, 219, 239–40, 244, 247, 251, 253, 276
Neuroimaging, 30, 102, 167. see also Magnetic resonance imaging
Neutrogenin, 10, 36, 39, 53, 196, 199, 212, 216, 265, 322, 322. see also NLGN1–4 in Gene Index
Neuronal migration. see Migration, cell/neuronal
Neuronal progenitor. see Progenitor, neuronal
Neuropilin, \(159, 161, 169\)
Next-generation sequencing. see Sequencing, next-generation
NF1 in Gene Index, 203, 217, 270, 323, 324, 325, 329
Nijmegen Breakage syndrome, 132
NLGN1–4 in Gene Index, 19, 37, 40, 57, 199, 208, 212, 263
NMDA receptor, 175, 197, 201–202, 208, 211, 213, 215–18, 321, 322, 325, 330
Non-allelic homologous recombination, 92
Non-shared environment. see Environment, non-shared
Noonan syndrome, 209
NRXN1 in Gene Index, 19, 37, 39, 57, 199, 208, 212
NuRD complex, 219
Nutrition, 29, 33, 34, 114, 121, 320
Obsessive compulsive disorder, 157, 170, 172, 199, 213–14, 296
Obstetric complications, 14, 33, 52, 54–5, 74, 201, 263
Penetration, high, 5, 16, 20, 39–40, 54–5, 75, 94, 263, 271, 299, 336
Penetration, incomplete, 5–6, 10, 11, 14, 16, 19, 74, 201, 263
Perception, 29, 163
Periventricular nodular heterotopia. see Heterotopia, periventricular nodular
Phelan-McDermid syndrome, 200, 208, 216, 263
Phenylketonuria, 282, 326
PKU. see Phenyketonuria
Plexin, \(159, 161–2, 165–6, 167–9\)
Polygene profile or score, 35, 120–21
Polygenic. see Inheritance, polygenic
Polymicrogyria, 134–5, 139–41, 143, 145
Polyorphism, copy number, 94
Polyorphism, single-nucleotide (SNP), 7–9, 13, 18–19, 34–6, 50, 60–61, 71–6, 91, 94–6, 99, 102, 119–21, 157, 167–8, 176, 267, 268. see also Variant, common
Porencephaly, 139
Postmortem, 146, 162, 168, 173, 239–40, 261, 321, 327, 335
Postsynaptic density, 196, 213, 215–17. see also Scaffolding proteins
Prader-Willi syndrome, 9, 37, 50, 243, 250, 276–7
Preimplantation genetic diagnosis, 241, 298
Prenatal diagnosis, 290, 292, 298
Privacy, 301–303
Progenitor, neuronal, 129–33, 137, 140–42, 146, 240, 244–7, 250–52
Proliferation, 116, 129–34, 137, 141–4, 158
Proteome or Proteomics, 70, 169–70, 209, 215, 290
Protocadherin, 196, 199, 212–13, 219. see also PCDHs in Gene Index
Pruning, axonal, dendritic or synaptic, 159, 162, 167, 173, 176, 197, 211, 281
Psychosis, 17, 19, 32, 36, 74, 100, 112, 118–19, 220–21, 237, 334, 336
Public health, 112, 116, 121
Quantitative trait, 3, 18, 70, 72–3, 121, 269
Rapamycin, 323, 325, 329, 331
Ras pathway, 116, 217, 324. see also GTPase
RASopathies, 218
Recurrence risk, 5, 19, 119
Resilience, 81
Rett syndrome, 1, 6, 10, 13, 29, 197, 205, 207, 213, 217, 219, 222, 243, 248–9, 269–70, 294, 321–3, 325–6, 328, 331–5
Robustness, 15, 299
Runs of heterozygosity, or ROH, 54, 91, 94–6, 99
Scaffolding proteins, 39, 196, 200, 211, 213, 215–16, 218
Schipzel-Giedion syndrome, 55–6
Schizophrenia, 134, 139, 141
Schizotypal disorder, 32
Season of birth, 33, 115, 117, 119–20
Seckel syndrome, 131–2
Segmental duplication, 92–4, 207–208
Segregation, 2, 5–6, 16, 18, 36, 52, 54–5, 94, 119, 132, 200
Seizures, 17, 30, 33–6, 39, 75, 130–33, 142–5, 201–205, 212, 218, 220–21, 247, 264, 266, 269, 276, 282, 321, 327, 329, 335
Selection, evolutionary, 3–5, 9, 51, 59–61, 72, 76, 82, 84, 87, 91–4, 97, 102, 114, 195, 275
Semaphorin, 159, 161–2, 164–6, 167–9, 196
Sequencing, exome, 12, 54–9, 195, 207, 209, 213, 219, 294, 298
Sequencing, next-generation, 10, 12, 57, 74, 129, 141, 145
Sequencing, whole-genome, 36, 39, 76, 290, 300, 303
Serotonin, 168, 172, 196, 217, 297, 322, 325
Shh. see Sonic Hedgehog
Sickle-cell anemia, 13
Single nucleotide variant. see Variant, single-nucleotide
SLI. see Language Impairment, Specific
Smith-Magenis syndrome, 50
SNP. see Polymorphism, single-nucleotide
SNV. see Variant, single-nucleotide
Socioeconomic status, 84, 278
Somatic mutation. see Mutation, somatic
Sonic Hedgehog, 144, 156, 245–7
Somatic mutation. see Mutation, somatic
Somatic mutation. see Mutation, somatic
Stem cell, embryonic, 241–7, 250
Stem cell, human pluripotent, 241, 243–6, 248, 252
Stem cell, induced pluripotent, 40, 221, 242–3, 246, 248–53, 264, 331–3
Stem cell, neural, 240, 246–7
Stem cell, pluripotent, 218, 221, 241, 248, 251
Strabismus, 136, 160, 162–3
Stress or Stressor, 82, 84–6, 97, 101–102, 114, 117, 119, 269, 281–2
Substance abuse, 95, 103
Substantia nigra, 171
Suppressor, genetic, 70, 269
Synapse formation, 133, 196, 198–205, 213–18, 220, see Synapse formation
Synaptic transmission, 49, 208–209, 211–12, 215, 218, 221, 264, 266, 328, 331
Synaptogenesis, 100, 166–9, 175, 196, 203, 209, 253, 326, 333, see also Synapse formation
Synecology, 258
Synthetic association, 9, 13
TALEN, 268
Tau, 173–4, 240, 252
Temporal lobe epilepsy, 32, 199, 215
Therapy, 18, 221–2, 248, 262, 267, 269, 283, 297, 301, 319, 326–31, 333–6
Timothy syndrome, 13, 34, 40, 201, 216, 221, 243, 248–9
TMS. see Transcranial magnetic stimulation
Tourette syndrome, 170, 199, 207–208, 212–14, 296
Toxoplasmosis, 29, 33, 114
Transcranial magnetic stimulation, 334
Transcription factor, 61, 161, 164, 166, 197, 205–206, 213, 218–20, 246
Transcriptome, 39, 290, 300
Transdifferentiation, 246
Translation (mRNA), 17, 49, 75, 197, 202, 210, 216, 217, 220, 322, 324, 329
Trauma, 11, 29, 118–19
Trisomy, 50, 83, 133, 240, 251–2, 276, 295, 300
TSC genes in Gene Index, 143, 210
Tuberous sclerosis, 1, 6, 74–5, 143, 197, 204, 217, 321–5, 328–9, 331, 335, see also TSC genes in Gene Index
Tubulin, 135–6, 140, 163
Turner syndrome, 243
Twins or twin studies, 11, 14–15, 18, 20, 32, 74–5, 85, 118–19, 277
Urbanicity, 117–19
Validity (construct, etiological, face or predictive), 18, 262–3, 268–9, 271
Valproate, 115
Variance, genetic, 8, 15, 18–19, 73, 297
Variant, common, 3–4, 7–9, 13–14, 16, 18–19, 39, 50, 60–61, 74, 75–6, 91, 167, 212, 267, 293–4
Variant, copy number. see CNV
Variant, rare, 4, 9, 16, 19, 39, 50, 58, 60–61, 74, 75, 91, 94, 99, 195, 293, 296. see also Mutation, rare and Variant, rare
Variant, single nucleotide, 10, 14, 55–61, 209, 219, 297. see also Mutation, rare and Variant, rare
Velocardiofacial syndrome, 1, 32, 36, 38, 141, 207, 291, 293–4, 296. see also 22q11.2
Vitamin D, 115, 117–18, 120
Waddington, C., 15, 72, 82, 299
Williams syndrome, 11, 37, 50, 207, 275, 282, 284
Williams-Beuren syndrome. see Williams syndrome
Wilmut, I., 243
Wnt, 144, 156, 161, 196, 219, 245–7
<table>
<thead>
<tr>
<th>X chromosome, 14, 50, 53, 101, 135–6, 141, 166, 252, 276, 332</th>
</tr>
</thead>
<tbody>
<tr>
<td>X chromosome inactivation, 135, 332</td>
</tr>
<tr>
<td>Xist, 252</td>
</tr>
<tr>
<td>X-linked female-limited epilepsy, 199, 207</td>
</tr>
<tr>
<td>X-linked intellectual disability (XLID), 52–3</td>
</tr>
<tr>
<td>Y chromosome, 13–14, 76</td>
</tr>
<tr>
<td>Yamanaka, S., 243</td>
</tr>
<tr>
<td>Zinc finger nuclease, 268</td>
</tr>
</tbody>
</table>